BeOne Medicines (ONC) Finished Goods (2017 - 2026)

BeOne Medicines (ONC) has 5 years of Finished Goods data on file, last reported at $298.2 million in Q1 2026.

• Quarterly Finished Goods changed N/A year-over-year to $298.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $298.2 million (changed N/A YoY) and the FY2025 annual result came in at $249.4 million, down 5.65% from the prior year.
• Finished Goods advanced to $298.2 million in Q1 2026 per ONC's latest filing, from $249.4 million in the prior quarter.
• Across five years, Finished Goods topped out at $298.2 million in Q1 2026 and bottomed at $249.4 million in Q4 2025.
• The 3-year median for Finished Goods is $264.3 million (2024), against an average of $270.6 million.
• Peak annual rise in Finished Goods reached 5.65% in 2025, while the deepest fall reached 5.65% in 2025.
• Tracing ONC's Finished Goods over 3 years: stood at $264.3 million in 2024, then retreated by 5.65% to $249.4 million in 2025, then rose by 19.57% to $298.2 million in 2026.
• Per Business Quant, the three latest ONC Finished Goods figures stand at $298.2 million (Q1 2026), $249.4 million (Q4 2025), and $264.3 million (Q4 2024).

Peer Comparison